Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients

Ascites related to metastatic colorectal cancer (mCRC) reduces patient survival and quality of life, and systemic chemotherapy is largely ineffective for managing ascites. Here, we examined the clinical efficacy of intraperitoneal (IP) ziv-aflibercept for managing refractory ascites in 15 mCRC patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chieh-Sheng, Lin, Jen-Kou, Chen, Wei-Shone, Lin, Tzu-Chen, Jiang, Jeng-Kai, Yang, Shung-Haur, Wang, Huann-Sheng, Chang, Shih-Ching, Lan, Yuan-Tzu, Lin, Chun-Chi, Lin, Hung-Hsin, Teng, Hao-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482690/
https://www.ncbi.nlm.nih.gov/pubmed/27888621
http://dx.doi.org/10.18632/oncotarget.13543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482690/
https://www.ncbi.nlm.nih.gov/pubmed/27888621
http://dx.doi.org/10.18632/oncotarget.13543

Ejemplares similares